Etzer Darout
Stock Analyst at BMO Capital
(2.90)
# 1,575
Out of 4,905 analysts
112
Total ratings
37.65%
Success rate
1.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $5.65 | +165.72% | 5 | May 13, 2025 | |
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $10.91 | +119.98% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.39 | +165.49% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $7.35 | +172.11% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $55.33 | +30.13% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $110.02 | +29.98% | 4 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Outperform | $91 → $96 | $63.26 | +51.75% | 6 | Feb 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $2.20 | +36.67% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.28 | +56.25% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $44.47 | -10.05% | 3 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $18.44 | +171.15% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.21 | +212.22% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $46.18 | +19.10% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $3.33 | +1,791.89% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.35 | +1,900.00% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $83.31 | +60.85% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $8.97 | +279.25% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $21.88 | +119.38% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $114.25 | +5.03% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $40.72 | -6.68% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.31 | +480.05% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.48 | +237.84% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.32 | +762.07% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.13 | +430.97% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $2.39 | +50.52% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $68.79 | +19.20% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $6.14 | +209.45% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $320.53 | -46.96% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $52.08 | +3.69% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $51.93 | -26.82% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.61 | +3,129.81% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $5.65
Upside: +165.72%
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $10.91
Upside: +119.98%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.39
Upside: +165.49%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.35
Upside: +172.11%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $55.33
Upside: +30.13%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $110.02
Upside: +29.98%
Merus
Feb 28, 2025
Maintains: Outperform
Price Target: $91 → $96
Current: $63.26
Upside: +51.75%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.20
Upside: +36.67%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.28
Upside: +56.25%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $44.47
Upside: -10.05%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $18.44
Upside: +171.15%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $11.21
Upside: +212.22%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $46.18
Upside: +19.10%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $3.33
Upside: +1,791.89%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.35
Upside: +1,900.00%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $83.31
Upside: +60.85%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $8.97
Upside: +279.25%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $21.88
Upside: +119.38%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $114.25
Upside: +5.03%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $40.72
Upside: -6.68%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.31
Upside: +480.05%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.48
Upside: +237.84%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.32
Upside: +762.07%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.13
Upside: +430.97%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $2.39
Upside: +50.52%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $68.79
Upside: +19.20%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $6.14
Upside: +209.45%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $320.53
Upside: -46.96%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $52.08
Upside: +3.69%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $51.93
Upside: -26.82%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.61
Upside: +3,129.81%